


22. II. Coexistent lymphoid or plasma cell neoplasms: A report of 20 cases unrelated to chemotherapy. Br J Haematol. 63, 149-159.


68. Brito-Babapulle V, Ellis J, Matutes E, Oscier D, Khokhar T, MacLennan K, Catovsky D. (1992) Translocation t(11;14)(q13;32) in chronic lymphoid disorders. Genes,


147. A Wiestner, A Rosenwald, TS Barry, G Wright, RE Davis, SE Henrickson, H Zhao, RE Ibbotson, JA Orchard, Z Davis, M Stetler-Stevenson, M Raffeld, DC Arthur, GE Marti,


166. MF McMullin, D Bareford, P Campbell, AR Green, C Harrison, B Hunt, D Oscier, MI Polkey, JT Reilly, E Rosenthal, K Ryan, TC Pearson, B Wilkins. Guidelines for the diagnosis, investigation and management of polycythemia/erythrocytosis. Br J Haematol,


171. SJ Richardson, C Matthews, MA Catherwood, HD Alexander, BS Carey, J Farrugia, A Gardiner, S Mould, D Oscier, JA Copplestone, AG Prentice. ZAP 70 expression is associated with enhanced ability to respond to migratory and survival signals in B CLL Blood. 107, 3584-92 2006.


177. AR Pettitt, E Matutes, D Oscier. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukemia patients with p53 defects. Leukemia. 20, 1441-5. 2006.


191. C Hidalgo-Curtis, A Chase, M Drachenberg, MW Roberts, JZ Finkelstein, S Mould, D Oscier, NC Cross, FH Grand. The t(1;9)(p34;q34) and t(8;12)(p11;q15) fuse pre-mRNA processing proteins SFPQ (PSF) and CPSF6 to ABL and FRFR1. Genes chromosomes and Cancer 2008.


213. Allan JM, Sunter NJ, Bailey JR, Pettitt A, Harris RJ, Pepper C, Fegan C, Hall AG,


Letters


Chapters


Abstracts


with myeloproliferative disorders. Br J Haematol. 71 No.1, 171.


suppl.10.


310. Gardiner AC, Corcoran MM, Oscier DG. (1995) Different regions of loss from
chromosome 13q14 translocations in B CLL determined by FISH using YAC probes. Br J Haematol, 89, suppl. 1, 80.


358. T. J. Hamblin, J. Orchard, R. Ibbotson, Z. Davis, P. Thomas, and F. K. Stevenson. CD38 expression and IgV gene mutations are independent prognostic factors in chronic lymphoproliferative leukemia (CLL) and can be used to select stage A patients for treatment. Br.J.Haematol. 113: 2001. (Abstract)


365. Oscier, DG, Davis,Z et al, VH gene analysis in Splenic Marginal Zone Lymphoma identifies patients with structurally similar B cell receptors but does not provide prognostic information. Blood 2006 108: 685a

366. Oscier, DG, Jones,A, Wallis,L Chacko,J Cross,NCP The Utility of V617F JAK2


377. Best OG, Gardiner AC, Davis Z, Ibbotson RE, Majid A, Dyer MJS, Oscier DG. A subset
of patients with TP53 abnormalities and mutated VH genes have stable disease. Leuk and Lymphoma 2007 48 Suppl 1:80.


387. Papadikis K’ Oscier D, Carr ESC, Lewis G, Aultman R. A UK cost-effectiveness analysis


398. Davis Z, Gardiner A, Oscier D. Associations between immunoglobulin gene stereotypy,


408. Hall S, Jones R, Killick S, Hall RL, Chacko JM, McCarthy H. A single- Centre Study of outcomes inpatients over 70 years old treated for B-cell Diffuse Large cell lymphoma (DLBCL); the impact of comorbidity scores. British Society Haematologists Annual meeting. Edinburgh April 2010


411. M Lasebai, RL Hall, H McCarthy A single centre experience of clonal evolution in relapsed myeloma manifested by light chain escape


